This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Vredevoe, D. L. Articles by Hays, E. F. Search for Related Content PubMed PubMed Citation Articles by Vredevoe, D. L. Articles by Hays, E. F.

Effect of Antilymphocytic and Antithymocytic Sera on the Development of Mouse Lymphoma¹

Laboratory of Nuclear Medicine and Radiation Biology, School of Nursing, and Department of Medicine, Center for the Health Sciences, University of California, Los Angeles, California 90024

Injections of antisera to lymphoid tissues of C3H/HeJ mice significantly increased the incidence of (a) lymphoma in normally resistant C3H/HeJ adult mice injected 4 times with Gross leukemia virus and (b) growth of allogeneic lymphomas in C3H/HeJ and AKR mice when compared to similarly treated animals injected with normal rabbit serum. The same antilymphoid cell sera were able to suppress sheep red blood cell hemagglutinin responses in parallel sets of mice.

Immunosuppressive drugs, 6-mercaptopurine (100 mg/kg of diet) and azathioprine (100, 150, or 200 mg/kg of diets or 150 mg/kg mouse injected intraperitoneally), did not increase the incidence of lymphoma in C3H/HeJ adult mice receiving multiple injections of Gross leukemia virus or depress the hemagglutinin response to sheep red blood cells.

There was a tendency towards prolongation of latent periods of spontaneous lymphoma in AKR mice and virus-induced lymphoma in C3H/HeJ mice injected with C3H/HeJ antithymocytic serum prior to development of lymphoma. Incidence and latent period of virus-accelerated lymphoma in AKR mice was not altered by administration of the antithymocytic serum during the latent period of lymphomagenesis.

¹ This investigation was supported in part by grants from the California Institute for Cancer Research, the Cancer Research Coordinating Committee, University of California, and Contract AT (04-1) GEN 12 between The Atomic Energy Commission and The University of California.

Received 11/22/68. Accepted 5/ 8/69.